References
- American Cancer Society. Cancer Facts and Figures 2013. Atlanta, Ga: American Cancer Society, 2013.
- National Comprehensive Cancer Network. NCCN Guidelines version 1.2012 – chronic myelogenous leukemia. Available online at: www.nccn.org/professionals/physician_gls/pdf/cml.pdf.
- European LeukemiaNet. Recommendations from the European LeukemiaNet for the management of chronic myeloid leukemia (CML). Available online at: www.leukemia-net.org/content/leukemias/cml/recommendations/.
- Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–561.
- Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
- Holloway S, Lord K, Bethelmie-Bryan B, et al. Managing chronic myeloid leukemia: A coordinated team care perspective. Clin Lymphoma Myeloma Leuk. 2012;12(2):88–93.